To examine whether pharmacological inactivation of BRPF1 could suppress HCC growth in vivo, we treated tumor-bearing nude mice with GSK5959 (30 mg/kg/day via intraperitoneal injection) for 2 weeks. Here, BRPF1 is linked to hepatocellular carcinoma.